Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00135759 · ClinicalTrials.gov registry record · Phase 2

Addition of Naltrexone to Methadone Taper

A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 2
Development phase
174
Enrollment target

NCT00135759: Completed Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).

NCT00135759 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 174 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00135759, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 2
Development phase
174 participants
Enrollment target

Study Summary

There is a continuing search for more effective opiate detoxification treatments. This study's purpose is to investigate the effects of adding very low doses of naltrexone to a methadone tapering treatment in opioid dependent individuals.

Interventions

  • DRUG Naltrexone
  • DRUG Placebo comparator
  • DRUG naltrexone

Trial Details

FieldValue
Enrollment Target 174 participants
Start Date 2005-04
Est. Completion 2006-07
Phase Phase 2

What the finished NCT00135759 record still lists

NCT00135759 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% higher).

The record links to 0 conditions, and to 3 interventions - of which Naltrexone is the first listed.

NCT00135759 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00135759 about?

NCT00135759 is a clinical study titled "Addition of Naltrexone to Methadone Taper". There is a continuing search for more effective opiate detoxification treatments. This study's purpose is to investigate the effects of adding very low doses of naltrexone to a methadone tapering treatment in opioid dependent individuals.

What is the current status of trial NCT00135759?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2005-04. Estimated completion is 2006-07.

What interventions are being tested in trial NCT00135759?

The interventions under investigation include: Naltrexone (DRUG), Placebo comparator (DRUG), naltrexone (DRUG).

Who is sponsoring clinical trial NCT00135759?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00135759's enrollment target sits among peer trials

174 396th of 2000 higher than 1,604 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01000259 · 174 participants

    Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

  • NCT04729114 · 174 participants · Phase 1

    A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

  • NCT04884035 · 174 participants · Phase 1

    Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

  • NCT05075980 · 174 participants · Phase 2

    Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00135759, the US trial registry maintained by the National Library of Medicine. NCT00135759 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.